BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, reporting beneficial ownership of 4,539,819 shares of Immix Biopharma common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock, Inc. reported beneficial ownership of 4,539,819 shares of Immix Biopharma common stock, representing 5.5% of the class.
  • Sole voting power: BlackRock reported sole voting power over 4,452,206 shares, with zero shared voting power.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 4,539,819 shares, with zero shared dispositive power.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Filer classification: BlackRock filed as a parent holding company or control person, incorporated in Delaware, with principal offices at 50 Hudson Yards, New York, NY 10001.
  • Ordinary course certification: The filing certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

BlackRock's Schedule 13G Filing on Immix Biopharma Common Stock

BlackRock, Inc. submitted a Schedule 13G disclosing a 5.5% beneficial ownership position in Immix Biopharma (CUSIP: 45258H106) as of the September 30, 2026 triggering date. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026. BlackRock is identified in the filing as a parent holding company organized in Delaware.

According to the filing, the 4,539,819 shares reported as beneficially owned include sole voting power over 4,452,206 shares and sole dispositive power over the full 4,539,819 shares. No shared voting or shared dispositive power was reported. The filing notes that the reported position reflects securities beneficially owned by certain designated business units of BlackRock and its subsidiaries and affiliates, and "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units."

On the question of third-party interests, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of IMMIX BIOPHARMA," but adds that "no one person's interest in the common stock of IMMIX BIOPHARMA is more than five percent of the total outstanding common shares." The identities of the relevant subsidiaries are referenced in Exhibit 99 attached to the filing.

What Was Disclosed

BlackRock, Inc. reported holding 4,539,819 shares, or 5.5%, of Immix Biopharma common stock as of September 30, 2026, with sole voting power over 4,452,206 shares and sole dispositive power over the full position, filed via Schedule 13G on October 27, 2026.